A bounded review of two randomized comparisons involving leuprolide: one pelvic-pain trial and one androgen-deprivation trial using leuprolide as the active comparator.12
Bottom line from this bounded source set
In the reviewed pelvic-pain trial, both treatment groups improved without a significant between-group difference. In the prostate-cancer trial, the oral comparator produced more sustained testosterone suppression than leuprolide; that biochemical endpoint does not establish a difference in cancer survival.12
Reviewed study record
Endometriosis-associated pelvic-pain trial
Design
A prospective, randomized, double-blind controlled trial compared leuprolide with continuous oral contraceptives over 48 weeks.1
Population
The trial enrolled 47 women with endometriosis-associated pelvic pain at academic medical centers in two U.S. cities.1
Outcomes reported
Pain and depression scores declined significantly from baseline in both groups, while the reported reductions did not differ significantly between groups.1
Limitations
The trial was small, and improvement within each group does not establish that the treatments were equivalent across broader populations or longer follow-up.1
Reviewed study record
HERO androgen-deprivation trial
Design
A sponsor-funded, randomized Phase 3 trial compared oral relugolix with leuprolide for 48 weeks; sustained testosterone suppression was the primary endpoint.2
Population
The trial randomized 930 men with advanced prostate cancer, including 308 assigned to leuprolide.2
Outcomes reported
Sustained testosterone suppression was reported for 96.7% of the relugolix group and 88.8% of the leuprolide group, meeting the trial's noninferiority and superiority criteria for that endpoint.2
Limitations
Leuprolide was the comparator, not the experimental treatment, and the primary result concerned testosterone suppression rather than cancer progression or survival.2
No registered Crossref update in the reviewed snapshotChecked August 19, 2026 for DOI 10.1016/j.fertnstert.2011.01.027. This bounded result is not proof that the publication has never been corrected or retracted. Open the pinned Crossref work endpoint ↗
No registered Crossref update in the reviewed snapshotChecked August 19, 2026 for DOI 10.1056/nejmoa2004325. This bounded result is not proof that the publication has never been corrected or retracted. Open the pinned Crossref work endpoint ↗